CoChat

Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia

The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.

Abstract

In a randomized, double-blind five-year trial, we tested the efficacy of simultaneously elevating serum levels of high-density lipoprotein (HDL) cholesterol and lowering levels of non-HDL cholesterol with gemfibrozil in reducing the risk of coronary heart disease in 4081 asymptomatic middle-aged men (40 to 55 years of age) with primary dyslipidemia (non-HDL cholesterol greater than or equal to 200 mg per deciliter [5.2 mmol per liter] in two consecutive pretreatment measurements). One group (2051 men) received 600 mg of gemfibrozil twice daily, and the other (2030 men) received placebo. Gemfibrozil caused a marked increase in HDL cholesterol and persistent reductions in serum levels of total, low-density lipoprotein (LDL), and non-HDL cholesterol and triglycerides. There were minimal changes in serum lipid levels in the placebo group. The cumulative rate of cardiac end points at five years was 27.3 per 1,000 in the gemfibrozil group and 41.4 per 1,000 in the placebo group--a reduction of 34.0 percent in the incidence of coronary heart disease (95 percent confidence interval, 8.2 to 52.6; P less than 0.02; two-tailed test). The decline in incidence in the gemfibrozil group became evident in the second year and continued throughout the study. There was no difference between the groups in the total death rate, nor did the treatment influence the cancer rates. The results are in accord with two previous trials with different pharmacologic agents and indicate that modification of lipoprotein levels with gemfibrozil reduces the incidence of coronary heart disease in men with dyslipidemia.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejm198711123172001

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

13 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 49 references

Research works printed but not linked: 8

  1. Nikkilä, 1953, Scand J Clin Lab Invest [Suppl], 5, 1
  2. Peto, 1985, Circulation, 72, III
  3. 1976, Proc R Soc Med, 69, 1
  4. Nikkilä, 1976, Proc R Soc Med, 69, 58
  5. Olsson, 1976, Proc R Soc Med, 69, 28
  6. Meinertz, 1986, R Soc Med Int Congr Symp Ser, 87, 15
  7. Pasternack, 1987, Clin Nephrol, 27, 163
  8. 1987, Eur Heart J, 8, 77

Cited by

See all 3,881

Metadata

Authors
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., Mäenpää, H., Mälkönen, M., Mänttäri, M., Norola, S., Pasternack, A., Pikkarainen, J., Romo, M., Sjöblom, T., & Nikkilä, E. A.
Affiliations
University of Helsinki (FI)
Venue
New England Journal of Medicine
Published
1987-11-12
Volume
317
Issue
20
Pages
1237-1245
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2341665659
Cited by
3,881
References
50
Citations by year
2026: 23 · 2025: 29 · 2024: 27 · 2023: 49 · 2022: 37 · 2021: 28 · 2020: 35 · 2019: 50 · 2018: 50 · 2017: 48 · 2016: 66 · 2015: 75 · 2014: 68 · 2013: 98 · 2012: 80
FWCI
257.96
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
gemfibrozil, primary prevention, coronary artery disease, dyslipidemia, HDL cholesterol, non-HDL cholesterol, LDL cholesterol, triglycerides, middle-aged men, lipid-lowering therapy, cardiovascular risk reduction
MeSH terms
Adult, Hypolipidemic Agents, Cholesterol, Clinical Trials as Topic, Coronary Disease, Double-Blind Method, Finland, Humans, Hypercholesterolemia, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Pentanoic Acids, Random Allocation, Risk Factors, Triglycerides, Valerates, Gemfibrozil

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia. https://app.cochat.ai/papers/10.1056/nejm198711123172001
The paper
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., Mäenpää, H., Mälkönen, M., Mänttäri, M., Norola, S., Pasternack, A., Pikkarainen, J., Romo, M., Sjöblom, T., & Nikkilä, E. A. (1987). Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia. New England Journal of Medicine. https://doi.org/10.1056/nejm198711123172001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.